enoxacin has been researched along with Hyperplasia in 1 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, EY | 1 |
| Shin, JH | 1 |
| Song, HY | 1 |
| Kim, JH | 1 |
| Lee, EW | 1 |
| Kim, WJ | 1 |
| Shin, DH | 1 |
| Lee, H | 1 |
1 other study available for enoxacin and Hyperplasia
| Article | Year |
|---|---|
Suppression of stent-induced tissue hyperplasia in rats by using small interfering RNA to target matrix metalloproteinase-9.
Topics: Animals; Cells, Cultured; Cholesterol; Drug Delivery Systems; Enoxacin; Esophagus; Hyperplasia; Male | 2014 |